VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Price history
Daily open, high, low, close and volume
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Daily prices are not in StockData yet. This table fills in once an end-of-day price source is connected. | ||||||
Stock splits
From SEC filings
| Date | Ratio | Effect on per-share figures |
|---|---|---|
| Jul 6, 2026(first seen in filings) | 1-for-25 reverse | Earlier per-share figures multiplied by 25 |
| Jun 26, 2026 | 1-for-25 reverse | Earlier per-share figures multiplied by 25 |
| Aug 20, 2024(first seen in filings) | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Dec 18, 2023 | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Jun 14, 2023(first seen in filings) | 15-for-4 | Earlier per-share figures divided by 3.75 |